Interpace Diagnostics (NASDAQ: IDXG) reported Q3 EPS of ($0.15). Revenue for the quarter came in at $4.2 million, versus $0 reported last year.

Q3 and Year-to-Date 2017 Financial Performance

• Net Revenue for the three-month period ended September 30, 2017 and for the nine-month period was $4.2 million and $11.5 million, respectively, an increase of 27% over the same prior year quarterly period and 16% over the same prior year-to-date period due principally to growth of units and reimbursement of our thyroid assays.
• Total Operating Expenses for the third quarter of 2017 were $5.2 million, a $2.7 million or 34% decrease from the same quarter of 2016, due principally to Asset Impairment charges in the prior year.
• Year-to-date Total Operating Expenses were $8.8 million, a reduction of $9.5 million from the prior year, due primarily to a Change in Fair Value of Contingent Consideration related to conversion of our then outstanding long-term debt to equity and termination of future related royalties and milestone obligations.
• Operating Loss for the quarter of $3.1 million improved $3.4 million or 52% from the same quarter of 2016.
• Operating Loss year-to-date in 2017 was $ 3.0 million, a 77% improvement compared to the prior year-to-date Operating Loss in 2016 of $13.2 million.
• Net Loss for the third quarter of 2017 of $3.3 million was $4.2 million or a 56% improvement from the third quarter Net Loss of $7.5 million for the same period in 2016.
• Year-to-date Net Loss of $7.2 million was $7.4 million less or a 51% improvement from the same year-to-date period of 2016.
• Our cash balance as of September 30, 2017 was $11.7 million.
• Net Cash Used in Operations for the third quarter of 2017 amounted to $4.3 million as compared to $1.3 million for the same quarter in 2016. Included in Net Cash Used in Operations in the third quarter of 2017 was approximately $2.0 million of expenditures related to discontinued operations, transaction fees and the remainder of payment obligations carried over from the discontinued contract sales organization (CSO) sold by us in 2015.
• Net Cash Used in Operations year-to-date 2017 was $12.9 million as compared to $6.7 million for the comparable period of 2016. Included in Net Cash Used in Operations year-to-date 2017 was approximately $4.7 million of expenditures related to discontinued operations, transaction fees and the remainder of payment obligations carried over from the CSO business we sold in 2015 as well as a reduction in payables, that were previously extended, of approximately $1.4 million.
• Total stockholders’ equity was $36.4 million as of September 30, 2017.

For earnings history and earnings-related data on Interpace Diagnostics (IDXG) click here.